{"publication_id":"6d41fa70-0327-4b55-b7b4-bad4c5449160","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP","doi":"10.1182/blood.2020008021","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative","doi":"10.1111/bjh.13658","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Thrombotic thrombocytopenic purpura temporally associated with BNT162b2 vaccination in an adolescent successfully treated with caplacizumab","doi":"10.1111/bjh.17782","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Artificial liver support system improves short- and long-term outcomes of patients with HBV-associated acute-on-chronic liver failure: a single-center experience.","doi":"10.1097/md.0000000000000338","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Early Plasmapheresis Among Patients With Hypertriglyceridemia–Associated Acute Pancreatitis","doi":"10.1001/jamanetworkopen.2023.20802","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis","doi":"10.1182/bloodadvances.2020001834","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"The etiology and mortality of new‐onset refractory status epilepticus (<scp>NORSE</scp>) in adults: A systematic review and meta‐analysis","doi":"10.1111/epi.17523","risk_of_bias":"not appraised in public sidecar","directness":"review-level"}]}